BQ-123 and BQ-788
PreclinicalSmall molecule
BQ-123 and BQ-788 is one of 9 small molecule programs targeting Vascular Function. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Vascular Function
#DrugCompanyPhaseTrials
1Voltaren
NovartisApproved
Ultram
WWim Janssens
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
Miochol
BBausch Health Americas, Inc.
Phase 1
L-Citrulline
AAsklepion Pharmaceuticals, LLC
Phase 1
S-Equol
AAusio Pharmaceuticals, LLC
Phase 2
Endothelin-1
MMedical University of Vienna
Phase 1
BH4
VVA Office of Research and Development
Phase 1
BQ-123 and BQ-788
MMedical University of Vienna
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ-123 and BQ-788. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical University of Vienna